Introduction: Chemotherapy (CT) is widely used for neuroendocrine tumors (NET) but there are no validated biomarkers to predict response. The Ki-67 proliferation index has been proposed as a means of selecting patients for CT but robust data are lacking.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr Alexa Childs